AROC-3 is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for Glomerulonephritis. According to GlobalData, Phase II drugs for Glomerulonephritis have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AROC-3’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AROC-3 overview
AROC-3 is under development for the treatment of adult patients with complement-mediated renal disease (C3 glomerulopathy [C3G] (glomerulonephritis) and IgA nephropathy [IgAN]). It acts by targeting complement component 3. The drug candidate is a siRNA developed which is based on Targeted RNAi Molecule (TRiM) platform. It is administered through subcutaneous route.
It was also under development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Arrowhead Pharmaceuticals overview
Arrowhead Pharmaceuticals (Arrowhead) is a biotech company that develops and commercializes gene silencing therapeutics. The company utilizes RNA chemistries and TRiM platform to target and silence disease-causing genes. Its pipeline products include ARO-AAT, ARO-APOC3, ARO-ANG3, ARO-PNPLA3, GSK4532990, ARO-C3, ARO-ENaC2, ARO-MUC5AC, ARO-RAGE, ARO-MMP7, ARO-COV, ARO-DUX4, ARO-SOD1, HZN-457, JNJ-3989 and Olpasiran. Arrowhead’s therapeutic areas include hypertriglyceridemia, dyslipidemia, facioscapulohumeral muscular dystrophy, complement-mediated diseases, much-obstructive or inflammatory pulmonary conditions, idiopathic pulmonary fibrosis, liver disease, gout, chronic hepatitis B and cardiovascular disease, among others. The company operates lab facilities in San Diego, California and Madison, Wisconsin, the US. Arrowhead is headquartered in Pasadena, California, the US.
For a complete picture of AROC-3’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
